Legende
: Rekrutierende Studie = 
; Fortlaufende Studie = 
-
- BELGIEN
- BRABANT WALLON
- LOUVAIN-LA-NEUVE
- Gait Evaluation in Haemophiliac Patients (observational).
- Pierre De Coubertin
- Institut d'Education Physique et Readaptation
- Mehr Details
-
- DEUTSCHLAND
- Berlin
- NOT YET IDENTIFIED - DE
- In vitro Evaluation von allergischen Reaktionen bei Hämophilie B Patienten, die eine systemische allergische Reaktion nach der Exposition mit BeneFix (Nonacog Alfa; Rekombinant-Faktor IX) gezeigt haben. (Phase IV) - Terminated
- Not yet identified - DE
- Mehr Details
-
- DEUTSCHLAND
- Berlin
- NOT YET IDENTIFIED - DE
- paradigm 2: Eine multizentrische einfachblinde Phase III-Studie zur Beurteilung der Sicherheit, Wirksamkeit und Pharmakokinetik von NNC-0156-0000-0009 in der Behandlung und Prophylaxe von Blutungen bei Patienten mit Hämophilie B
- Not yet identified - DE
- Mehr Details
-
- DEUTSCHLAND
- Berlin
- NOT YET IDENTIFIED - DE
- Eine Phase II / III offene, multizentrische, Sicherheits- und Wirksamkeits-Studie mit rekombinantem Blutgerinnungsfaktor-IX-Albuminfusionsprotein (rIX-FP) bei Patienten mit Hämophilie B
- Not yet identified - DE
- Mehr Details
-
- FRANKREICH
- ILE-DE-FRANCE
- PARIS
- An Exploratory Multi-Centre, Multi-National, Randomised, Double Blinded, Parallel Arm Trial Evaluating Safety, Pharmacokinetics and Dose-finding of prophylactic administration of Long Acting rFVIIa (LA-rFVIIa) in Haemophilia A or B Patients with Inhibitors (Phase II) - FR
- CHU Paris - Hôpital Necker - Enfants Malades
- Centre Régional de traitement de l'hémophilie François Josso
- Mehr Details
-
- FRANKREICH
- NORD-PAS-DE-CALAIS
- LILLE
- FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor (Phase III) - FR
- CHRU de Lille - Centre de biologie et pathologie
- Service Hématologie-Transfusion
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- LYON
- B-LONG: An open-label multicenter study evaluating the safety, pharmacokinetics and efficacy of the Fc-recombinant, Long-acting Coagulation Factor IX (rFIXFc) fusion protein in the prevention and treatment of bleeding in previously treated patients with severe hemophilia B - FR
- CHRU Lyon - Hôpital Edouard Herriot
- Centre régional de traitement de l'hémophilie
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- LYON
- Phase I/II/III pharmacokinetic and outcome study of Inspiration's recombinant Factor IX product, IB1001, in subjects with hemophilia B - FR
- CHRU Lyon - Hôpital Edouard Herriot
- Centre régional de traitement de l'hémophilie
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX) (Phase IV) - FR
- Not yet identified - FR
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 4: Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B - FR
- Not yet identified - FR
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 3: An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - FR
- Not yet identified - FR
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 2: A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC-0156-0000-0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemophilia B - FR
- Not yet identified - FR
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B - FR
- Not yet identified - FR
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- FEIBA NF: A prospective, open-label, randomized, parallel study to evaluate efficacy and safety of prophylactic versus on-demand treatment in subjects with hemophilia A or B and a high titer inhibitor - FR
- Not yet identified - FR
- Mehr Details
-
- FRANKREICH
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Phase 1/2, Prospective, Dose-Escalation/Finding Study to Evaluate Pharmacokinetics and Immediate Tolerability of Recombinant Activated FVII (rFVIIa BI) in Patients with Hemophilia A or B and Inhibitors - FR
- Not yet identified - FR
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- FERRARA
- Gentamycin treatment of congenital coagulation factor VII or factor IX deficiency caused by nonsense mutations (phase II)
- Università degli Studi di Ferrara
- Laboratorio di Biologia Molecolare dell'Emostasi e Trombosi
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor (Phase III) - IT
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 2: A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC-0156-0000-0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 3: An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 4: Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase II/III open-label, multicenter, safety and efficacy study of a recombinant coagulation Factor IX Albumin Fusion Protein (rIX-FP) in subjects with Hemophilia B - IT
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 5: Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase II-III trial to evaluate the efficacy and safety of BAY86-6150
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- ITALIEN
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B
- NOT YET IDENTIFIED - IT
- Mehr Details
-
- SPANIEN
- Cataluña
- BARCELONA
- Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B (completed)
- Hospital Universitari General Vall d'Hebron
- Unidad de Hemofilia
- Mehr Details
-
- SPANIEN
- Cataluña
- BARCELONA
- BAX 326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B - A Continuation Study - ES
- Hospital Universitari General Vall d'Hebron
- Unidad de Hemofilia
- Mehr Details
-
- SPANIEN
- Madrid
- NOT YET IDENTIFIED - ES
- Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors (Phase III) - ES (completed)
- Not yet identified - ES
- Mehr Details
-
- SPANIEN
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B - ES
- Not yet identified - ES
- Mehr Details
-
- SPANIEN
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B
- Not yet identified - ES
- Mehr Details
-
- SPANIEN
- Madrid
- NOT YET IDENTIFIED - ES
- An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Patients With Haemophilia B (Phase III) - ES
- Not yet identified - ES
- Mehr Details
-
- SPANIEN
- Madrid
- NOT YET IDENTIFIED - ES
- Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B (Phase III) - ES
- Not yet identified - ES
- Mehr Details
-
- VEREINIGTES KONIGREICH
- Greater London
- LONDON
- An open label dose-escalation study of a self complementary adeno-associated viral vector (scAAV2/8-LP1-hFIXCO) for gene therapy of haemophilia B (Phase I/II)
- University College London
- Department of Haematology
- Mehr Details
